Zytiga (Abiraterone)

Zytiga (abiraterone) is a CYP17 inhibitor used in combination with prednisone for the treatment of patients with:
metastatic castration-resistant prostate cancer (CRPC).
metastatic high-risk castration-sensitive prostate cancer (CSPC).

Recommended Dosage:
Recommended Dose for Metastatic CRPC: The recommended dose of Abiraterone is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.
Recommended Dose for Metastatic High-risk CSPC: The recommended dose of Abiraterone is 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily with prednisone 5 mg administered orally once daily.

Patients receiving Abiraterone should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking this drug. Swallow the tablets whole with water. It is not advisable to crush or chew tablets.

• Treatment with Abiraterone 250 mg/500 mg may cause mineralocorticoid excess. This may cause low potassium levels, high blood pressure, or fluid retention. Regularly monitor blood pressure and electrolytes. Administer a corticosteroid to reduce these effects and manage symptoms early to avoid serious cardiovascular complications in at-risk patients.
• Patients treated with this medicine can develop adrenocortical insufficiency, mainly during stress or corticosteroid withdrawal. Symptoms may include low blood pressure, fatigue, or electrolyte imbalance. Monitor adrenal function and adjust corticosteroid dose accordingly to maintain hormonal balance and prevent adrenal-related issues.
• Liver enzyme elevations and critical liver injury may occur during treatment. Regularly monitor liver function tests, mainly in the first months. Interrupt or stop treatment if significant hepatotoxicity is reported. Patients with preexisting liver complications must be managed with caution.
• Combining this medicine with Radium Ra 223 Dichloride may elevate the probability of bone fractures and death. DO not use both treatments simultaneously unless necessary. Assess benefits versus risks, and consider alternative therapy in case combination treatment is being considered.
• This treatment may increase the effect of antidiabetic medicines. This may increase the risk of low blood sugar levels. Monitor blood glucose frequently in diabetic patients and adjust antidiabetic medicine dosage if required to prevent hypoglycemia during Abiraterone 250 mg/500 mg treatment.
• This medicine can cause harm to an unborn baby and is contraindicated in those who are or may become pregnant. Consider effective contraception for female partners of male patients. Use relevant safeguards and counsel on reproductive risks before starting treatment.
• It is not specified whether abiraterone is excreted in human milk, but because of the potential for critical side effects, do not breastfeed during treatment. Patients should avoid breastfeeding and discuss alternative feeding methods while on abiraterone therapy.

What documents are required to import ZYTIGA to India?

ZYTIGA (abiraterone) tablets can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is ZYTIGA available in India?

ZYTIGA (abiraterone tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Zytiga in India (Mumbai, Kolkata,
• Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada,
• Europe, and Australia
• Ensuring 100% transparency.

ZYTIGA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ZYTIGA (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Zytiga 250 mg/500 mg Tablet price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source ZYTIGA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Zytiga®?

Abiraterone acetate is the Generic Name for the trade name drug Zytiga®.

What is the Manufacturer's Name of Zytiga®?

Zytiga® is manufactured by Centocor Ortho Biotech Inc..

What is the dosage and form of Zytiga® supplied?

Zytiga is supplied in Tablets: 250 mg, and 500 mg for oral administration.

What are the most common side effects of Zytiga® 250 mg/500 mg Tablets?

The most common side effects of Zytiga® are nausea, fatigue, vomiting, arthralgia, hypertension, edema, cough, hypokalemia, hot flush, diarrhea, upper respiratory infection, and headache.

How much does Zytiga® 250 mg/500 mg Tablet cost in India?

Prices of Zytiga tablets may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Zytiga 250 mg/500 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Zytiga® 250 mg/500 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Zytiga® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Zytiga® tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Zytiga® 250 mg/500 mg Tablets online in India?

Yes, one can buy Zytiga 250 mg/500 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Zytiga® tablets through legal channels.

What are the storage conditions of Zytiga® 250 mg/500 mg Tablets?

Store tablets at 20 to 25 °C (68 to 77 °F); excursions permitted in the range from 15 to 30 °C (59 to 86 °F). Keep this therapeutic drug out of reach of children.